東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Preclinical Evaluation of a Novel An...

Zarabi, Sarah F.

FindBook

Google Book

Amazon

博客來

Preclinical Evaluation of a Novel Anti-leukemic Mechanism.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Preclinical Evaluation of a Novel Anti-leukemic Mechanism./
作者:	Zarabi, Sarah F.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2020,
面頁冊數:	178 p.
附註:	Source: Dissertations Abstracts International, Volume: 82-01, Section: B.
Contained By:	Dissertations Abstracts International82-01B.
標題:	Biophysics. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=27548732
ISBN:	9798662388925

Preclinical Evaluation of a Novel Anti-leukemic Mechanism.
Zarabi, Sarah F.

Preclinical Evaluation of a Novel Anti-leukemic Mechanism. - Ann Arbor : ProQuest Dissertations & Theses, 2020 - 178 p.

Source: Dissertations Abstracts International, Volume: 82-01, Section: B.

Thesis (Ph.D.)--University of Toronto (Canada), 2020.

This item must not be sold to any third party vendors.

Acute Myeloid Leukemia (AML) is a heterogeneous disease that is associated with a remarkably diverse group of genetic mutations that contribute to its biological complexity directly, or indirectly by triggering downstream cellular reactions. Given these complexities, identification of a single therapeutic strategy that can be effective against a wide range of AML subgroups remains challenging and very few effective novel antileukemic agents have been developed in the past 30 years. Consequently, the overall outcome of patients with AML remains poor. Despite aggressive chemotherapies, AML patients may not achieve remission even after two courses of induction (primary non-responders). Here, our retrospective data indicate that in primary non-responders with AML, remissions following a third induction course are uncommon and short-lived if not consolidated by stem cell transplant (SCT) . Thus, our data indicates that a 3rd induction should only be offered to primary non-responders with AML if an SCT strategy is in place. Collectively, this background highlights an urgent need for development of novel antileukemic strategies.ClpP is a mitochondrial protease that is overexpressed in leukemic cells from approximately half of patients with AML. It degrades damaged or misfolded proteins inside mitochondria and has a central role in maintaining the integrity of mitochondrial metabolism by functioning as a protein quality control mediator. Herein, through genetic and chemical investigations, we demonstrate that ClpP activation results in prominent anti-leukemia and anti-lymphoma effects. We identified a new class of antineoplastic compounds -imipridones- as potent ClpP activators. ClpP activation induces cell death in leukemia and lymphoma cells and stem cells and exerts antitumor effects in vivo whereas normal hematopoietic cells display resistance. In primary AML samples, sensitivity to ClpP activators correlates with pre-treatment ClpP expression level. Mechanistically, binding of imipridones to ClpP enhances proteolysis by enlarging the axial pores of the enzyme. ClpP activation impairs oxidative phosphorylation through reductions in respiratory chain complex subunits and abrogates mitochondrial morphology and function. The currently most potent ClpP activators, imipridones, are being evaluated in clinical trials. Our approach provides groundwork for further development of ClpP activators and represents a first-in-class therapeutic strategy for a subset of hematologic malignancies.

ISBN: 9798662388925Subjects--Topical Terms:

518360
Biophysics.
Subjects--Index Terms:

AML

Preclinical Evaluation of a Novel Anti-leukemic Mechanism.
LDR:03646nmm a2200373 4500 001 2270058
005 20200921070613.5
008 220629s2020 ||||||||||||||||| ||eng d
020 $a 9798662388925
035 $a (MiAaPQ)AAI27548732
035 $a AAI27548732
040 $a MiAaPQ $c MiAaPQ
100 1 $a Zarabi, Sarah F. $3 3547426
245 1 0 $a Preclinical Evaluation of a Novel Anti-leukemic Mechanism.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2020
300 $a 178 p.
500 $a Source: Dissertations Abstracts International, Volume: 82-01, Section: B.
500 $a Advisor: Schimmer, Aaron D.
502 $a Thesis (Ph.D.)--University of Toronto (Canada), 2020.
506 $a This item must not be sold to any third party vendors.
520 $a Acute Myeloid Leukemia (AML) is a heterogeneous disease that is associated with a remarkably diverse group of genetic mutations that contribute to its biological complexity directly, or indirectly by triggering downstream cellular reactions. Given these complexities, identification of a single therapeutic strategy that can be effective against a wide range of AML subgroups remains challenging and very few effective novel antileukemic agents have been developed in the past 30 years. Consequently, the overall outcome of patients with AML remains poor. Despite aggressive chemotherapies, AML patients may not achieve remission even after two courses of induction (primary non-responders). Here, our retrospective data indicate that in primary non-responders with AML, remissions following a third induction course are uncommon and short-lived if not consolidated by stem cell transplant (SCT) . Thus, our data indicates that a 3rd induction should only be offered to primary non-responders with AML if an SCT strategy is in place. Collectively, this background highlights an urgent need for development of novel antileukemic strategies.ClpP is a mitochondrial protease that is overexpressed in leukemic cells from approximately half of patients with AML. It degrades damaged or misfolded proteins inside mitochondria and has a central role in maintaining the integrity of mitochondrial metabolism by functioning as a protein quality control mediator. Herein, through genetic and chemical investigations, we demonstrate that ClpP activation results in prominent anti-leukemia and anti-lymphoma effects. We identified a new class of antineoplastic compounds -imipridones- as potent ClpP activators. ClpP activation induces cell death in leukemia and lymphoma cells and stem cells and exerts antitumor effects in vivo whereas normal hematopoietic cells display resistance. In primary AML samples, sensitivity to ClpP activators correlates with pre-treatment ClpP expression level. Mechanistically, binding of imipridones to ClpP enhances proteolysis by enlarging the axial pores of the enzyme. ClpP activation impairs oxidative phosphorylation through reductions in respiratory chain complex subunits and abrogates mitochondrial morphology and function. The currently most potent ClpP activators, imipridones, are being evaluated in clinical trials. Our approach provides groundwork for further development of ClpP activators and represents a first-in-class therapeutic strategy for a subset of hematologic malignancies.
590 $a School code: 0779.
650 4 $a Biophysics. $3 518360
650 4 $a Cellular biology. $3 3172791
650 4 $a Medicine. $3 641104
653 $a AML
653 $a ClpP
653 $a Imipridone
653 $a Mitochondria
653 $a Primary non-responders
690 $a 0786
690 $a 0379
690 $a 0564
710 2 $a University of Toronto (Canada). $b Medical Biophysics. $3 3181600
773 0 $t Dissertations Abstracts International $g 82-01B.
790 $a 0779
791 $a Ph.D.
792 $a 2020
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=27548732